Document Type : Original Article


Department of Clinical Science, Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran


Ovariohysterectomy (OHE) is one of the most common surgeries in veterinary medicine. Although this surgical method has several advantages, it can alter the function of various organs such as heart. The present study investigated the effect of OHE on cardiac functions using M-mode echocardiography. A total of 10 healthy adult domestic short-haired cats were enrolled in the current study. Fractional shortening (FS) and ejection fraction (EF) percentages along with cardiac output (CO) were measured through the right parasternal approach in papillary muscle level view. Moreover, the levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were measured by enzyme-linked immunosorbent assay before OHE (D0) as well as 10 (D10), 20 (D20) and 30 (D30) days after OHE. The results of this study showed that the mean FS and EF decreased on all days of the study. The FS reduction was significant between D10 and D30 and EF changes were significant between D10 and D20. The means of CO increased significantly on D0 compared to the D10. After D20, CO reduced until the end of the study. Mean concentrations of LH and FSH increased on all research days; but, the changes were significant until D20. Despite the negative effects of OHE on myocardial function, there was no significant correlation between hormonal levels and echocardiographic findings after OHE in this study.


Main Subjects

  1. Mohamed AA, Arifi AA, Omran A. The basics of echocardiography. J Saudi Heart Assoc 2010; 22(2): 71-76.
  2. Groban L, Yamaleyeva LM, Westwood BM, et al. Progressive diastolic dysfunction in the female mRen (2). Lewis rat: influence of salt and ovarian hormones. J Gerontol A Biol Sci Med Sci 2008; 63(1): 3-11.
  3. Wang H, Jessup JA, Lin MS, et al. Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2. Lewis rats. Cardiovasc Res 2012; 94(1): 96-104.
  4. Düzenli MA, Ozdemir K, Sokmen A, et al. Effects of menopause on the myocardial velocities and myocardial performance index. Circ J 2007; 71(11): 1728-1733.
  5. Vadakkadath Meethal S, Atwood CS. The role of hypothalamic-pituitary-gonadal hormones in the normal structure and functioning of the brain. Cell Mol Life Sci 2005; 62(3): 257-270.
  6. Beijerink NJ, Buijtels JJ, Okkens AC, et al. Basal and GnRH-induced secretion of FSH and LH in anestrous versus ovariectomized bitches. Theriogenology 2007; 67(5): 1039-1045.
  7. Choijookhuu N, Hino S-i, Oo PS, et al. The role of estrogen receptors in intestinal homeostasis and disease. Receptor Clin Invest 2016; 3. e1109. doi: 10.14800/rci.1109.
  8. López M, Tena-Sempere M. Estrogens and the control of energy homeostasis: a brain perspective. Trends Endocrinol Metab 2015; 26(8): 411-421.
  9. Lønning Estradiol measurement in translational studies of breast cancer. Steroids 2015; 99(Pt A): 26-31.
  10. Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014; 65(3): 565-573.
  11. Stilley JA, Guan R, Duffy DM, et al. Signaling through FSH receptors on human umbilical vein endothelial cells promotes angiogenesis. J Clin Endocrinol Metab 2014; 99(5): E813-E820.
  12. Pinthus JH. Follicle-stimulating hormone: A potential surrogate marker for androgen deprivation therapy oncological and systemic effects. Can Urol Assoc J 2015; 9(3-4): E226-E227.
  13. Tivesten Å, Pinthus JH, Clarke N, et al. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms. Urol Oncol 2015: 33(11): 464-475.
  14. Crawford ED, Schally AV, Pinthus JH, et al. The potential role of follicle-stimulating hormone in the cardio-vascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol 2017: 35(5): 183-191.
  15. Moise NS, Dietze AE, Mezza LE, et al. Echocardiography, electrocardiography, and radiography of cats with dilatation cardiomyopathy, hypertrophic cardiomyo-pathy, and hyperthyroidism. Am J Vet Res 1986; 47(7): 1476-1486.
  16. Sisson DD, Knight DH, Helinski C, et al. Plasma taurine concentrations and M‐mode echocardiographic measures in healthy cats and in cats with dilated cardiomyopathy. J Vet Intern Med 1991; 5(4): 232-238.
  17. Barp J, Araújo AS, Fernandes TR, et al. Myocardial antioxidant and oxidative stress changes due to sex hormones. Braz J Med Biol Res 2002; 35(9): 1075-1081.
  18. Vitale C, Mendelsohn ME, Rosano GM. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol 2009; 6(8): 532-542.
  19. Zhao D, Guallar E, Ouyang P, et al. Endogenous sex hormones and incident cardiovascular disease in post-menopausal women. J Am Coll Cardiol 2018; 71(22): 2555-2566.
  20. Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009; 94(7): 2482-2488.
  21. Sievers C, Klotsche J, Pieper L, et al. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Eur J Endocrinol 2010; 163(4): 699-708.
  22. Sickinghe AA, Korporaal SJ, den Ruijter HM, et al. Estrogen contributions to microvascular dysfunction evolving to heart failure with preserved ejection fraction. Front Endocrinol (Lausanne) 2019; 10: 442. doi: 10.3389/fendo.2019.00442
  23. Zhu D, Chung HF, Pandeya N, et al. Premenopausal cardiovascular disease and age at natural menopause: a pooled analysis of over 170,000 women. Eur J Epidemiol 2019; 34(3): 235-246.
  24. Zhu D, Chung HF, Dobson AJ, et al. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies. Am J Obstet Gynecol 2020; 223(6): 898. e1-898.e16. doi: 10.1016/j.ajog.2020.06.039.
  25. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation 2020; 142(25): e506-e532.
  26. Nappi RE, Simoncini T. Menopause transition: a golden age to prevent cardiovascular disease. Lancet Diabetes Endocrinol 2021; 9(3): 135-137.
  27. Grohé C, Kahlert S, Löbbert K, et al. Modulation of hypertensive heart disease by estrogen. Steroids 1996; 61(4): 201-204.
  28. Massafra C, Gioia D, De Felice C, et al. Effects of estrogens and androgens on erythrocyte antioxidant superoxide dismutase, catalase and glutathione peroxidase activities during the menstrual cycle. J Endocrinol 2000; 167(3): 447-452.
  29. Bednarek-Tupikowska G, Bohdanowicz-Pawlak A, Bidzińska B, et al. Serum lipid peroxide levels and erythrocyte glutathione peroxidase and superoxide dismutase activity in premenopausal and post-menopausal women. Gynaecol Endocrinol 2001; 15(4): 298-303.
  30. Serviddio G, Loverro G, Vicino M, et al. Modulation of endometrial redox balance during the menstrual cycle: relation with sex hormones. J Clin Endocrinol Metab 2002; 87(6): 2843-2848.
  31. Briasoulis A, Tousoulis D, Antoniades C, et al. The oxidative stress menace to coronary vasculature: any place for antioxidants? Curr Pharma Des 2009; 15(26): 3078-3090.